Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer
More than half of patients with treatment-refractory HER2-positive non-small cell lung cancer (NSCLC) responded to an anti-HER2 antibody-drug conjugate, data from a preliminary trial showed. Fifty of 91 patients responded to trastuzumab deruxtecan (T-DXd) and another 34 patients had stable disease, resulting in a disease control rate exceeding 90%. Responses were durable in many cases, […]